Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

QRxPharma successfully completes phase III pilot study of MoxDuo IR

April 22, 2009

Taisho presents novel heterocyclic compounds for the treatment of pain

April 22, 2009

Alkylsulfone derivatives claimed by Daiichi Sankyo for the treatment of Alzheimer's disease

April 22, 2009

Psylin Neurosciences begins development of PSN-004 for depression

April 21, 2009

Phytopharm initiates safety and tolerability study of PYM-50028 in PD

April 21, 2009

Forest and Cypress launch Savella for fibromyalgia

April 21, 2009

Impax provides clinical update on IPX-066 and IPX-056

April 21, 2009

Cannabinoid CB2 modulators claimed by Kalypsys as analgesics

April 21, 2009

PAION initiates phase Ib study of CNS-7056 in volunteers undergoing colonoscopy

April 20, 2009

Dainippon discontinues development of AC-3933 for dementia

April 20, 2009

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...